Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

This observational pre-screening study is identifying people with Stargardt disease — an inherited condition that causes progressive vision loss — who may be eligible to participate in future clinical trials of a treatment called ACDN-01. Researchers are conducting a series of eye and genetic tests to assess eligibility before the main clinical trials begin, so that participants can be matched to trials more efficiently. People with confirmed mutations in the ABCA4 gene and a diagnosis of Stargardt disease type 1 or cone-rod dystrophy may be eligible, unless they have other retinal diseases or serious medical or psychiatric conditions. Participation involves eye assessments and genetic testing at a single visit. This summary was prepared to help patients understand the study in plain language.